An investigational extended-release minoxidil could change how we treat thinning hair. Here’s what we know so far.
For decades, the options for pattern hair loss have felt frustratingly familiar: a topical foam you apply twice a day, a pill with hormonal side effects, or a hair transplant. Now a new contender is moving through late-stage clinical trials, and it has the hair-care world paying attention. Its name is VDPHL01.
What is VDPHL01?
VDPHL01 is an investigational drug developed by Veradermics. It is an oral extended-release formulation of minoxidil, which was originally designed to treat resistant hypertension. The company is developing it as a non-hormonal treatment for pattern hair loss in both men and women. iposcoop
Minoxidil is no newcomer. It remains the only drug approved for hair growth in both men and women. What’s different here is the delivery. Veradermics uses a proprietary extended-release technology designed to extend the exposure of hair follicles to minoxidil over time. biospacebusinesswire
Why the extended-release design matters
Oral minoxidil is already prescribed off-label by some dermatologists, but standard tablets weren’t built for hair. The idea behind VDPHL01 is to maximize the plasma concentrations of minoxidil known to grow hair without inducing changes in cardiac activity. In simple terms, the aim is steady, targeted exposure rather than sharp peaks, which is where a purpose-built formulation could add value. iposcoop
What do the trials show?
The program has moved quickly:
- Phase 2 (early signals): Preliminary data showed that after two months of twice-daily treatment, patients had more thickened, normally pigmented hairs, with no serious side effects reported. biospace
- Phase 3 in men: The company reported that VDPHL01 met every primary and secondary endpoint in its second Phase 3 trial, Study ‘304’, which enrolled 536 men. tikr
- Women: Positive topline results came from the open-label Phase 2 Study ‘207’ in female pattern hair loss, showing rapid onset and consistent hair growth with strong tolerability. quartr
- Long-term safety: Twelve-month safety data from another study, ‘302’, is expected later this year. tikr
These are company-reported results. Independent analysis and the full peer-reviewed data will matter when they arrive.
Who is it for?
Pattern hair loss, also called androgenetic alopecia, is enormous in scale. The company estimates it affects roughly 50 million men and 30 million women in the United States. Many people quit topical treatments because of the daily routine, which is why a simple once-or-twice-daily tablet is so appealing to patients and dermatologists alike. renaissancecapital
Is VDPHL01 approved yet?
No. As of this writing, VDPHL01 is still investigational. No products have been approved or commercialized by Veradermics yet. The company has said it intends to file a New Drug Application with the FDA, but approval is never guaranteed and timelines can shift. If you’re considering treatment now, your best move is to talk to a dermatologist about options that are available today. quartr
The bottom line
VDPHL01 is one of the more closely watched hair loss programs in development. It builds on a familiar, proven molecule and tries to make it work better through formulation. Early and Phase 3 results are encouraging, but the real test will be long-term safety data, regulatory review, and how it compares with the cheap generics already on the market.
We’ll keep this post updated as new data and regulatory news come in.
Related reading: Oral vs. Topical Minoxidil: What’s the Difference? · How Pattern Hair Loss Works
